Most active investors · All time

Ranked by rounds participated in, from announcements across all periods. Lead counts include only confirmed lead roles.

Browse by month

211

FactoryLatest Aug 26

Transfyr · $25M Seed Radical Numerics · $50M Seed

2rounds

—led

Biotech 2

Seed 2

Aug 26, 2026

Details

New companies 2 · Follow-on 0

Stages: Seed 2

Transfyr $25M Seed Radical Numerics $50M Seed

212

SV InvestmentLatest Aug 19

KaliVir Immunotherapeutics · $14M Series A BreezeBio · $60M Series B

2rounds

—led

Biotech 2

Series A 1, Series B 1

Aug 19, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series B 1

KaliVir Immunotherapeutics $14M Series A BreezeBio $60M Series B

213

Mass General Brigham VenturesLatest Aug 18

Abcuro · $66M Series D Violet Therapeutics · $4.8M Seed+

2rounds

—led

Biotech 2

Seed 1, Series C+ 1

Aug 18, 2026

Details

New companies 2 · Follow-on 0

Stages: Seed 1, Series C+ 1

Abcuro $66M Series D Violet Therapeutics $4.8M Seed+

214

Chugai Venture FundLatest Aug 17

Leal Therapeutics · $30M Series A Ten63 Therapeutics · $45M Strategic

2rounds

—led

AI 1Biotech 1

Series A 1, Undisclosed 1

Aug 17, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Undisclosed 1

Leal Therapeutics $30M Series A Ten63 Therapeutics $45M Strategic

215

Newpath PartnersLatest Aug 17

Leal Therapeutics · $30M Series A CREATE Medicines · $122M Series B

2rounds

—led

Biotech 2

Series A 1, Series B 1

Aug 17, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series B 1

Leal Therapeutics $30M Series A CREATE Medicines $122M Series B

216

Emerson CollectiveLatest Aug 12

InduPro · $77M Series B Ultralight · $9.3M Seed

2rounds

—led

Biotech 1Healthtech 1

Seed 1, Series B 1

Aug 12, 2026

Details

New companies 2 · Follow-on 0

Stages: Seed 1, Series B 1

InduPro $77M Series B Ultralight $9.3M Seed

217

Qumra CapitalLatest Aug 12

Remepy · $36M Series A QuantHealth · $45M Series B

2rounds

—led

Biotech 2

Series A 1, Series B 1

Aug 12, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series B 1

Remepy $36M Series A QuantHealth $45M Series B

218

Root Venture PartnersLatest Aug 12

Beyang Therapeutics · $30M Series A CORE Biomedicine · $21M Series A

2rounds

—led

Biotech 2

Series A 2

Aug 12, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 2

Beyang Therapeutics $30M Series A CORE Biomedicine $21M Series A

219

SanofiLatest Aug 12

InduPro · $77M Series B Altesa BioSciences · $75M Series B

2rounds

—led

Biotech 2

Series B 2

Aug 12, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 2

InduPro $77M Series B Altesa BioSciences $75M Series B

220

MedicxiLatest Aug 11

Vaderis Therapeutics · $152M Series B Altesa BioSciences · $75M Series B

2rounds

—led

Biotech 2

Series B 2

Aug 11, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 2

Vaderis Therapeutics $152M Series B Altesa BioSciences $75M Series B

221

Pear VCLatest Aug 11

Infinimmune · $75M Series A Portal Biotechnologies · $9M Undisclosed

2rounds

—led

Biotech 2

Series A 1, Undisclosed 1

Aug 11, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Undisclosed 1

Infinimmune $75M Series A Portal Biotechnologies $9M Undisclosed

222

HighLight CapitalLatest Aug 10

Aureka Biotechnologies · $100M Series B Vivatides Therapeutics · $54M Series A

2rounds

—led

Biotech 2

Series A 1, Series B 1

Aug 10, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series B 1

Aureka Biotechnologies $100M Series B Vivatides Therapeutics $54M Series A

223

MPCiLatest Aug 10

Aureka Biotechnologies · $100M Series B Excalipoint Therapeutics · $27.7M Seed+

2rounds

—led

Biotech 2

Seed 1, Series B 1

Aug 10, 2026

Details

New companies 2 · Follow-on 0

Stages: Seed 1, Series B 1

Aureka Biotechnologies $100M Series B Excalipoint Therapeutics $27.7M Seed+

224

BNP Paribas Asset Management AltsLatest Aug 5

Vedanta Biosciences · $60M Growth ILiAD Biotechnologies · $115M Series B

2rounds

—led

Biotech 2

Growth 1, Series B 1

Aug 5, 2026

Details

New companies 2 · Follow-on 0

Stages: Growth 1, Series B 1

Vedanta Biosciences $60M Growth ILiAD Biotechnologies $115M Series B

225

Boost VCLatest Aug 5

SkinBit · $6M Pre-Seed Claryx · $3.5M Pre-Seed

2rounds

—led

Biotech 1Healthtech 1

Pre-seed 2

Aug 5, 2026

Details

New companies 2 · Follow-on 0

Stages: Pre-seed 2

SkinBit $6M Pre-Seed Claryx $3.5M Pre-Seed

226

Gates FrontierLatest Aug 5

LifeMine Therapeutics · $263M Series D+Series E Cellares · $257M Series D

2rounds

—led

Biotech 2

Series C+ 1, Undisclosed 1

Aug 5, 2026

Details

New companies 2 · Follow-on 0

Stages: Series C+ 1, Undisclosed 1

LifeMine Therapeutics $263M Series D+Series E Cellares $257M Series D

227

Milky Way InvestmentsLatest Aug 5

LifeMine Therapeutics · $263M Series D+Series E Parabilis Medicines · $305M Series F

2rounds

—led

Biotech 2

Series C+ 1, Undisclosed 1

Aug 5, 2026

Details

New companies 2 · Follow-on 0

Stages: Series C+ 1, Undisclosed 1

LifeMine Therapeutics $263M Series D+Series E Parabilis Medicines $305M Series F

228

Scottish National Investment BankLatest Aug 5

Mironid · $46M Series B EnteroBiotix · £19M Series B

2rounds

0led

Biotech 2

Series B 2

Aug 5, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 2

Mironid $46M Series B EnteroBiotix £19M Series B

229

Bertelsmann Healthcare InvestmentsLatest Aug 4

QuantHealth · $45M Series B Flinn · $20M Series A

2rounds

—led

Biotech 1Healthtech 1

Series A 1, Series B 1

Aug 4, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series B 1

QuantHealth $45M Series B Flinn $20M Series A

230

Mana VenturesLatest Aug 4

Claryx · $3.5M Pre-Seed Kanvas Biosciences · $48M Series A

2rounds

—led

Biotech 2

Pre-seed 1, Series A 1

Aug 4, 2026

Details

New companies 2 · Follow-on 0

Stages: Pre-seed 1, Series A 1

Claryx $3.5M Pre-Seed Kanvas Biosciences $48M Series A

231

DSC InvestmentLatest Aug 3

Inocras · $31M Series B BreezeBio · $60M Series B

2rounds

—led

Biotech 2

Series B 2

Aug 3, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 2

Inocras $31M Series B BreezeBio $60M Series B

232

InterVestLatest Aug 3

Inocras · $31M Series B Galux · $29M Series B

2rounds

—led

Biotech 2

Series B 2

Aug 3, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 2

Inocras $31M Series B Galux $29M Series B

233

Korea Investment & SecuritiesLatest Aug 3

Inocras · $31M Series B Galux · $29M Series B

2rounds

—led

Biotech 2

Series B 2

Aug 3, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 2

Inocras $31M Series B Galux $29M Series B

234

LoftyRock InvestmentLatest Aug 3

Inocras · $31M Series B BreezeBio · $60M Series B

2rounds

—led

Biotech 2

Series B 2

Aug 3, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 2

Inocras $31M Series B BreezeBio $60M Series B

235

Oak HC/FTLatest Aug 3

Dash Bio · $30M Series A Chai Discovery · $400M Series C

2rounds

—led

Biotech 2

Series A 1, Series C+ 1

Aug 3, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series C+ 1

Dash Bio $30M Series A Chai Discovery $400M Series C

236

Mitsubishi UFJ Capital CoLatest Jul 28

CORE Biomedicine · $21M Series A Rege Nephro Co · $10.6M Series C

2rounds

—led

Biotech 2

Series A 1, Series C+ 1

Jul 28, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series C+ 1

CORE Biomedicine $21M Series A Rege Nephro Co $10.6M Series C

237

Oxford University InnovationLatest Jul 23

Moa Technology · £22.2M Series C RQ Bio · $115M Series A

2rounds

—led

Agritech 1Biotech 1

Series A 1, Series C+ 1

Jul 23, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series C+ 1

Moa Technology £22.2M Series C RQ Bio $115M Series A

238

ParkwalkLatest Jul 23

Moa Technology · £22.2M Series C Semarion · $3.8M Undisclosed

2rounds

—led

Agritech 1Biotech 1

Series C+ 1, Undisclosed 1

Jul 23, 2026

Details

New companies 2 · Follow-on 0

Stages: Series C+ 1, Undisclosed 1

Moa Technology £22.2M Series C Semarion $3.8M Undisclosed

239

Mayo ClinicLatest Jul 22

Transcripta Bio · $24M Series A Syntax Bio · $14.4M Series A+

2rounds

—led

Biotech 2

Series A 2

Jul 22, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 2

Transcripta Bio $24M Series A Syntax Bio $14.4M Series A+

240

AngelorLatest Jul 20

Brenus Pharma · €11M Series A Standing Ovation · €30M Series B

2rounds

—led

Biotech 1Foodtech 1

Series A 1, Series B 1

Jul 20, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series B 1

Brenus Pharma €11M Series A Standing Ovation €30M Series B

“—” in Led means every role for that investor in this period is undisclosed; it does not mean zero leads. New companies counts the first participation in a company in our records; follow-on counts later participation.